Cell cycle inhibitors basically interrupt the growth proteins in order to slow or even stop the progression of the cell cycle. Cell cycle arrest can be induced at any point during the cell cycle, slowing cell division and reducing the number of actively cycling cells. The cell cycle inhibitors aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body and generally make the process slower or completely stop the cell division.
This report contains market size and forecasts of Cell Cycle Inhibitors in Global, including the following market information:
Global Cell Cycle Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cell Cycle Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CDK4 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cell Cycle Inhibitors include Sanofi, Syros Pharmaceuticals, Piramal Enterprises, Pfizer, NMS Group, G1 Therapeutics, Eli Lilly and Company, Cyclacel Pharmaceuticals and F. Hoffmann-La Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cell Cycle Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cell Cycle Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cell Cycle Inhibitors Market Segment Percentages, by Type, 2021 (%)
CDK4 Inhibitors
CDK9 Inhibitors
CDK6 Inhibitors
Others
Global Cell Cycle Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cell Cycle Inhibitors Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Others
Global Cell Cycle Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cell Cycle Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cell Cycle Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cell Cycle Inhibitors revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Syros Pharmaceuticals
Piramal Enterprises
Pfizer
NMS Group
G1 Therapeutics
Eli Lilly and Company
Cyclacel Pharmaceuticals
F. Hoffmann-La Roche
Regeneron Pharmaceuticals
Teva Pharmaceuticals Industries
Sanofi
Genentech
Sanofi Regeneron Pharmaceuticals
BioCAD GLOBAL
Bayer AG
Otsuka America
Amgen
ANYGEN